Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07447557 · ClinicalTrials.gov registry record · Phase 1
Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)
A Phase 1 study, sponsored by Elpida Therapeutics SPC.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07447557 is a Phase 1 study that is actively recruiting participants, run by Elpida Therapeutics SPC. The registered enrollment target is 8 participants.
The verdict
NCT07447557, a Phase 1 study, is actively recruiting participants, sponsored by Elpida Therapeutics SPC.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
First-in-human Phase 1/2, open-label study to evaluate the safety, tolerability, and efficacy of a single lumbar intrathecal dose of ELP-02 to individuals with CMT4J.
Interventions
- GENETIC ELP-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-07 |
| Est. Completion | 2032-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07447557
The ClinicalTrials.gov registry entry for NCT07447557 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Elpida Therapeutics SPC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ELP-02 is the first listed.
NCT07447557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07447557 about?
NCT07447557 is a clinical study titled "Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)". First-in-human Phase 1/2, open-label study to evaluate the safety, tolerability, and efficacy of a single lumbar intrathecal dose of ELP-02 to individuals with CMT4J.
What is the current status of trial NCT07447557?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-07. Estimated completion is 2032-12.
What interventions are being tested in trial NCT07447557?
The interventions under investigation include: ELP-02 (GENETIC).
Who is sponsoring clinical trial NCT07447557?
This trial is sponsored by Elpida Therapeutics SPC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.